A Must-Read Baffling Response from Health Canada’s Adam Gibson as NHPPA Wraps Up the Rebuttal Package to 308 MPs Riding Chart: Step 2
STEP 2 OF THE CHARTER TO 308 MPS CAMPAIGN: REBUTTAL PACKAGE CAME TO A CLOSE ON JULY 18.
Since then NHPPA part time staff and volunteers have been preparing and mailing the Rebuttal Packages to remaining MPs. When we’re done we’ll be sending out an interesting post-campaign report that includes the final delivery numbers for Step 2, a particularly odd response from an MP and the campaign’s next steps.
In the mean time you don’t want to miss reading a recent letter from the Director General of the NNHPD*, Adam Gibson, in response to an active NHPPA member’s complaint about nattokinase being unavailable. It seems impossible to understand how Mr. Gibson’s letter includes the following statements about nattokinase when a report cites 281 deaths and 1700 adverse reactions linked to Pradaxa from the time it was approved by Health Canada:
“In order for a NHP to be approved for use in Canada, companies must provide Health Canada with evidence regarding its safety, quality and efficacy.”
“Since blood thinners carry a risk of internal bleeding, the Department requires data supporting their safe use. In Canada, companies wishing to sell products containing nattokinase did not include sufficient evidence to support this ingredient in their original applications. Therefore, the Department contacted these companies and gave them another opportunity to demonstrate that the benefits of nattokinase outweigh the risks, and that the product(s) can be used safely.”
We feel that the contents of this letter, alone, warrants a response. Let us know if you’d like NHPPA to prepare a direct reply for a national citizen’s send to Mr. Gibson.
* NHPD has changed its name to NNHPD Natural and Non-prescription Health Products Directorate